The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tau

Tau pathology is characterized as a form of frontotemporal lobar degeneration (FTLD) known as FTLD-tau. The underlying pathogenic mechanisms are not known and no therapeutic interventions are currently available. Here, we report that the neurotrophin receptor p75NTR plays a critical role in the path...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular psychiatry 2018-08, Vol.23 (8), p.1813-1824
Hauptverfasser: Shen, Lin-Lin, Mañucat-Tan, Noralyn B., Gao, Shi-Hao, Li, Wei-Wei, Zeng, Fan, Zhu, Chi, Wang, Jun, Bu, Xian-Le, Liu, Yu-Hui, Gao, Chang-Yue, Xu, Zhi-Qiang, Bobrovskaya, Larisa, Lei, Peng, Yu, Jin-Tai, Song, Weihong, Zhou, Hua-Dong, Yao, Xiu-Qing, Zhou, Xin-Fu, Wang, Yan-Jiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tau pathology is characterized as a form of frontotemporal lobar degeneration (FTLD) known as FTLD-tau. The underlying pathogenic mechanisms are not known and no therapeutic interventions are currently available. Here, we report that the neurotrophin receptor p75NTR plays a critical role in the pathogenesis of FTLD-tau. The expression of p75NTR and the precursor of nerve growth factor (proNGF) were increased in the brains of FTLD-tau patients and mice (P301L transgenic). ProNGF-induced tau phosphorylation via p75NTR in vitro, which was associated with the AKT/glycogen synthase kinase (GSK)3β pathway. Genetic reduction of p75NTR in P301L mice rescued the memory deficits, alleviated tau hyperphosphorylation and restored the activity of the AKT/GSK3β pathway. Treatment of the P301L mice with the soluble p75NTR extracellular domain (p75ECD-Fc), which can antagonize neurotoxic ligands of p75NTR, effectively improved memory behavior and suppressed tau pathology. This suggests that p75NTR plays a crucial role in tau paGSKthology and represents a potential druggable target for FTLD-tau and related tauopathies.
ISSN:1359-4184
1476-5578
DOI:10.1038/s41380-018-0071-z